Assessing germline genetic testing patterns, awareness, and adherence to guidelines among lebanese prostate cancer patients
- 1Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon
- 2Department of Hematology-Oncology, Hotel- Dieu de France University Hospital, Beirut, Lebanon
- 3Center Jacques Loiselet for medical genetics and genomics (CGGM), Saint Joseph University of Beirut, Beirut, Lebanon
Abstract
Introduction: Prostate cancer is the most common cancer in men worldwide and the second most lethal after lung cancer. Despite poor prognosis for metastatic cases, treatment advances have extended survival. However, data on germline genetic testing in Lebanese prostate cancer patients is scarce. This study investigates the frequency and role of genetic testing in prostate cancer management in Lebanon, focusing on its impact on treatment decisions.
Methods: Pathogenic variant status was assessed using an NGS panel. Data from the Saint Joseph University genetic lab (2013–2022) was analyzed, including demographics, diagnosis year, testing dates, and treatment outcomes. Referral patterns between oncologists and urologists were compared, and the use of PARP inhibitors was discussed.
Results: Only 20 patients were referred for genetic testing over 12 years. Our study’s low referral rates reflect real-world data from a third-country setting. Among these, 15% were referred by urologists and 85% by oncologists. Of those tested, 20% were positive, two with BRCA2 mutations and two with MSH2 variants. Testing was mostly done after disease progression or metastasis, four were referred due to family history. None of the positive patients received PARP inhibitors.
Conclusion: The study revealed low genetic testing referral rates, consistent with global trends despite updated guidelines. Contributing factors include complex guidelines, limited provider awareness, and high testing costs. Interestingly, these factors are more pronounced in the context of our study. Improved education, clearer guidelines, and telemedicine access could boost genetic testing uptake, enhancing prostate cancer treatment standards and survival rates locally and globally, with a particular focus on developing countries including Lebanon.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12894-026-02300-4.
Related
- Adherence to French guidelines on cuff leak test use across French intensive care units: a national survey
- Exploring the role of local sequence context on patterns of germline mutation
- Predictors of Adherence to Syndromic Management Guidelines for Community-Based Management of Sexually Transmitted Infections: An Original Cross-Sectional Study
- ADHERENCE PATTERNS AND THEIR DETERMINANTS TO CFTR MODULATORS IN FRANCE
- Inhaled treatment adherence patterns and related barriers across three monthly follow-up waves among patients with cough variant asthma: a clinical natural language processing study
BibTeX
@article{seif2026assessing,
title = {{Assessing germline genetic testing patterns, awareness, and adherence to guidelines among lebanese prostate cancer patients}},
author = {Samah Seif and Tala Najdi and Alain Chebly and Marita Bassil and Nour Bou Atme and Rouba Khnaisser and Joseph Kattan},
journal = {BMC Urology},
year = {2026},
month = aug,
doi = {10.1186/s12894-026-02300-4},
url = {https://doi.org/10.1186/s12894-026-02300-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Assessing germline genetic testing patterns, awareness, and adherence to guidelines among lebanese prostate cancer patients
AU - Samah Seif
AU - Tala Najdi
AU - Alain Chebly
AU - Marita Bassil
AU - Nour Bou Atme
AU - Rouba Khnaisser
AU - Joseph Kattan
PY - 2026
DA - 2026/08/08
JO - BMC Urology
DO - 10.1186/s12894-026-02300-4
UR - https://doi.org/10.1186/s12894-026-02300-4
AB - Introduction: Prostate cancer is the most common cancer in men worldwide and the second most lethal after lung cancer. Despite poor prognosis for metastatic cases, treatment advances have extended survival. However, data on germline genetic testing in Lebanese prostate cancer patients is scarce. This study investigates the frequency and role of genetic testing in prostate cancer management in Lebanon, focusing on its impact on treatment decisions. Methods: Pathogenic variant status was assessed using an NGS panel. Data from the Saint Joseph University genetic lab (2013–2022) was analyzed, including demographics, diagnosis year, testing dates, and treatment outcomes. Referral patterns between oncologists and urologists were compared, and the use of PARP inhibitors was discussed. Results: Only 20 patients were referred for genetic testing over 12 years. Our study’s low referral rates reflect real-world data from a third-country setting. Among these, 15% were referred by urologists and 85% by oncologists. Of those tested, 20% were positive, two with BRCA2 mutations and two with MSH2 variants. Testing was mostly done after disease progression or metastasis, four were referred due to family history. None of the positive patients received PARP inhibitors. Conclusion: The study revealed low genetic testing referral rates, consistent with global trends despite updated guidelines. Contributing factors include complex guidelines, limited provider awareness, and high testing costs. Interestingly, these factors are more pronounced in the context of our study. Improved education, clearer guidelines, and telemedicine access could boost genetic testing uptake, enhancing prostate cancer treatment standards and survival rates locally and globally, with a particular focus on developing countries including Lebanon. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12894-026-02300-4.
SN - 1471-2490
ER -